MX385975B - Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1. - Google Patents

Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1.

Info

Publication number
MX385975B
MX385975B MX2018009952A MX2018009952A MX385975B MX 385975 B MX385975 B MX 385975B MX 2018009952 A MX2018009952 A MX 2018009952A MX 2018009952 A MX2018009952 A MX 2018009952A MX 385975 B MX385975 B MX 385975B
Authority
MX
Mexico
Prior art keywords
acetylcholine receptor
positive allosteric
allosteric modulators
muscarinic acetylcholine
compounds
Prior art date
Application number
MX2018009952A
Other languages
English (en)
Other versions
MX2018009952A (es
Inventor
Craig W Lindsley
Darren W Engers
Julie L Engers
Katrina A Bollinger
P Jeffrey Conn
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of MX2018009952A publication Critical patent/MX2018009952A/es
Publication of MX385975B publication Critical patent/MX385975B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen moduladores alostéricos positivos del receptor de acetilcolina muscarínico M1 (mAChR M1), composiciones farmacéuticas que incluyen los compuestos, y métodos para usar los compuestos y composiciones para tratar trastornos neurológicos, trastornos psiquiátricos o una combinación de los mismos.
MX2018009952A 2016-02-16 2017-02-16 Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1. MX385975B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662296012P 2016-02-16 2016-02-16
US201662402438P 2016-09-30 2016-09-30
PCT/US2017/018140 WO2017143041A1 (en) 2016-02-16 2017-02-16 Positive allosteric modulators of the muscarinic acetylcholine receptor m1

Publications (2)

Publication Number Publication Date
MX2018009952A MX2018009952A (es) 2018-11-29
MX385975B true MX385975B (es) 2025-03-18

Family

ID=59626207

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009952A MX385975B (es) 2016-02-16 2017-02-16 Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1.

Country Status (15)

Country Link
US (1) US11111251B2 (es)
EP (1) EP3416639B1 (es)
JP (1) JP2019504901A (es)
KR (1) KR20180110132A (es)
CN (1) CN109069491A (es)
AU (1) AU2017221404A1 (es)
BR (1) BR112018016689A2 (es)
CA (1) CA3014791A1 (es)
CL (1) CL2018002335A1 (es)
EA (1) EA201891854A1 (es)
IL (1) IL261058A (es)
MA (1) MA44253A (es)
MX (1) MX385975B (es)
PH (1) PH12018501731A1 (es)
WO (1) WO2017143041A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000554T1 (it) 2016-09-02 2020-11-10 Suven Life Sciences Ltd Modulatori allosterici positivi del recettore muscarinico m1
EA035599B1 (ru) * 2017-04-13 2020-07-14 Сувен Лайф Сайенсиз Лимитед Позитивные аллостерические модуляторы мускариновых m1-рецепторов
PT3643718T (pt) 2017-06-20 2023-10-26 Takeda Pharmaceuticals Co Composto heterocíclico e seu uso como modulador alostérico positivo do recetor muscarínico colinérgico m1
AU2018289939B2 (en) * 2017-06-20 2022-06-16 Takeda Pharmaceutical Company Limited Heterocyclic compound
US11299481B2 (en) 2017-10-20 2022-04-12 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
NZ763341A (en) * 2017-10-27 2023-03-31 Suven Life Sciences Ltd Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
EP3703680B1 (en) 2017-10-31 2024-05-15 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
JP7352294B2 (ja) 2018-02-02 2023-09-28 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
WO2019241467A1 (en) * 2018-06-13 2019-12-19 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
US11970483B2 (en) 2018-09-28 2024-04-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US12162864B2 (en) 2018-09-28 2024-12-10 Takeda Pharmaceutical Company Limited Condensed-cyclic compound
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
WO2020086864A1 (en) 2018-10-24 2020-04-30 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
JP7572734B2 (ja) 2019-10-04 2024-10-24 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608079A (en) 1983-08-02 1986-08-26 American Cyanamid Company Imidazolidinones, and imidazolidinethiones, process and intermediates for the preparation thereof, and use of said compounds as herbicidal agents
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
KR20010102543A (ko) 1999-03-09 2001-11-15 로렌스 티. 마이젠헬더 항바이러스제로서의4-옥소-4,7-디히드로-티에노[2,3-ｂ]피리딘-5-카르복스아미드
AU5919001A (en) 2000-04-28 2001-11-12 Acadia Pharm Inc Muscarinic agonists
MXPA04003007A (es) * 2001-10-02 2004-07-15 Upjohn Co Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades.
BR112012014180A2 (pt) * 2009-12-17 2015-09-15 Merck Sharp & Dohme composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio.
US8815902B2 (en) 2010-06-15 2014-08-26 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide M1 receptor positive allosteric modulators
EP2709621B1 (en) * 2011-05-17 2016-11-02 Merck Sharp & Dohme Corp. N-linked quinolineamide m1 receptor positive allosteric modulators
US20160200733A1 (en) 2013-08-23 2016-07-14 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
TW201512197A (zh) 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
GB201317363D0 (en) * 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
WO2015110370A1 (en) 2014-01-22 2015-07-30 F. Hoffmann-La Roche Ag Fluoro-naphthyl derivatives
WO2015190564A1 (ja) * 2014-06-13 2015-12-17 武田薬品工業株式会社 含窒素複素環化合物
WO2016009297A1 (en) * 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016029454A1 (en) 2014-08-29 2016-03-03 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
SMT202000554T1 (it) 2016-09-02 2020-11-10 Suven Life Sciences Ltd Modulatori allosterici positivi del recettore muscarinico m1

Also Published As

Publication number Publication date
MX2018009952A (es) 2018-11-29
JP2019504901A (ja) 2019-02-21
EP3416639A1 (en) 2018-12-26
PH12018501731A1 (en) 2019-06-17
AU2017221404A1 (en) 2018-08-23
WO2017143041A1 (en) 2017-08-24
US20210230180A1 (en) 2021-07-29
CN109069491A (zh) 2018-12-21
CL2018002335A1 (es) 2019-02-01
CA3014791A1 (en) 2017-08-24
MA44253A (fr) 2018-12-26
EP3416639A4 (en) 2019-07-03
BR112018016689A2 (pt) 2019-02-12
EP3416639B1 (en) 2022-06-08
US11111251B2 (en) 2021-09-07
IL261058A (en) 2018-10-31
EA201891854A1 (ru) 2019-01-31
KR20180110132A (ko) 2018-10-08

Similar Documents

Publication Publication Date Title
MX385975B (es) Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1.
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CL2016002661A1 (es) Compuestos derivados de isoindolin-1-ona, con actividad del receptor colinérgico muscarínico m1 del modulador alostérico positivo; composición farmacológica; útiles para el tratamiento del alzheimer, esquizofrenia, dolor, trastornos del sueño, demencia asociada al parkinson o demencia con cuerpos de lewy.
CL2017003127A1 (es) Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico m1 colinergico.
ECSP17074645A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
CL2018002697A1 (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos.
CO2018013077A2 (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas
CL2016000726A1 (es) Derivados de 4-azaindol
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
MX2016014773A (es) Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosomico.
ECSP17081322A (es) Moduladores alostéricos positivos del receptor muscarínico m2
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CL2016002497A1 (es) “compuestos derivados de heterociclos condensados sustituidos, moduladores de gpr119; composición farmacéutica que los comprende; útiles en el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados”. pct
MX2018002446A (es) Compuestos heterociclicos fusionados como moduladores s1p.
CL2019002583A1 (es) Inhibidores duales de magl y faah.
BR112018016629A2 (pt) moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
CL2020000360A1 (es) Compuestos de indazol como potenciadores alostericos mglur4, composiciones y métodos de tratamiento de la disfunción neurológica.
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa
MX379454B (es) Derivados de fluoroindol como moduladores alostéricos positivos del receptor m1 muscarínico.
MX2022008016A (es) Compuesto antagonista de pd-l1.
MX394670B (es) Agentes anticancerigenos y preparacion de los mismos.
MA50806A (fr) Azacycles substitués utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1